pembrolizumab and lenvatinib


( Last Updated : August 4, 2022)
Generic Name:
pembrolizumab and lenvatinib
Project Status:
Active
Therapeutic Area:
Advanced endometrial cancer
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda and Lenvima
Project Line:
Reimbursement Review
Project Number:
PC0288-000
Tumour Type:
Genitourinary
NOC Status at Filing:
Post NOC

Details


Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Tumour Type:
Genitourinary
Indications:
Keytruda in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.
Date NOC Issued:

Submit Feedback

Key Milestones

Submission received 07-Mar-22
Submission accepted 21-Mar-22
Review initiated 22-Mar-22
Draft CADTH review report(s) provided to sponsor for comment 24-May-22
Deadline for sponsors comments 02-Jun-22
CADTH review report(s) and responses to comments provided to sponsor 30-Jun-22
Expert committee meeting (initial) 13-Jul-22
Draft recommendation issued to sponsor 26-Jul-22
Draft recommendation posted for stakeholder feedback 04-Aug-22
End of feedback period 18-Aug-22